The long non‐coding RNA antisense 1 ADAMTS9-AS1 has been reported to predict the survival in several tumors, including bladder cancer and breast cancer. However, the clinical significance and biological behaviors of ADAMTS9-AS1 in colorectal cancer (CRC) have not been reported yet. In this study, the expression of ADAMTS9-AS1 was measured in CRC tissues and cell lines using quantitative real-time PCR analysis. The clinical significance of ADAMTS9-AS1 was evaluated with Chi-squared test, Kaplan–Meier method and Cox regression analysis in CRC patients. CCK8 assay, colony formation assay, flow cytometry and transwell assay were used to explore the biological function of ADAMTS9-AS1 knockdown in CRC cell lines (SW1116 and HT29). We further explore the role of ADAMTS9-AS1 in vivo though xenograft tumor assay. Our data showed that ADAMTS9-AS1 expression level was significantly up-regulated in CRC tissues and cell lines compared with corresponding controls. High ADAMTS9-AS1 level was associated with TNM stage, lymph node invasion and worse survival prognosis. Depletion of ADAMTS9-AS1 significantly suppressed cell proliferation, G1/S transition, migration and invasion, as well as suppressed CDK4/Cyclin D1 and epithelial–mesenchymal transition (EMT). To sum up, these findings illustrated that ADAMTS9-AS1 might be a promising therapeutic target and prognostic factor for CRC.

据报道，长链非编码 RNA 反义 1 ADAMTS9-AS1 可预测多种肿瘤的存活率，包括膀胱癌和乳腺癌。然而，ADAMTS9-AS1在结直肠癌（CRC）中的临床意义和生物学行为尚未见报道。在这项研究中，使用定量实时 PCR 分析测量了 CRC 组织和细胞系中 ADAMTS9-AS1 的表达。通过卡方检验、Kaplan-Meier 法和 Cox 回归分析评估 ADAMTS9-AS1 在 CRC 患者中的临床意义。CCK8 测定、集落形成测定、流式细胞术和 transwell 测定用于探索 ADAMTS9-AS1 敲低在 CRC 细胞系（SW1116 和 HT29）中的生物学功能。我们通过异种移植肿瘤试验进一步探索 ADAMTS9-AS1 在体内的作用。我们的数据显示，与相应的对照相比，结直肠癌组织和细胞系中 ADAMTS9-AS1 的表达水平显着上调。高 ADAMTS9-AS1 水平与 TNM 分期、淋巴结侵犯和较差的生存预后相关。ADAMTS9-AS1 的消耗显着抑制细胞增殖、G1/S 转变、迁移和侵袭，以及抑制 CDK4/Cyclin D1 和上皮-间质转化 (EMT)。综上所述，这些发现表明 ADAMTS9-AS1 可能是 CRC 的一个有希望的治疗靶点和预后因素。G1/S 转变、迁移和侵袭，以及抑制 CDK4/Cyclin D1 和上皮-间质转变 (EMT)。综上所述，这些发现表明 ADAMTS9-AS1 可能是 CRC 的一个有希望的治疗靶点和预后因素。G1/S 转变、迁移和侵袭，以及抑制 CDK4/Cyclin D1 和上皮-间质转变 (EMT)。综上所述，这些发现表明 ADAMTS9-AS1 可能是 CRC 的一个有希望的治疗靶点和预后因素。